PRODUCT DEVELOPMENT PIPELINE
Deciphera’s proprietary switch control platform has generated a broad clinical pipeline of kinase inhibitors including tumor-targeted therapies and immuno-targeted therapies.
KINASE SWITCH CONTROL INHIBITOR PLATFORM
Deciphera's switch control inhibitors are designed to address key limitations of current cancer therapies by selectively blocking kinase activation.
LATEST NEWS
